Blood & Marrow Clinical Trials Network- Hutchinson Center as Core Clinical Site

血

• 批准号: 10430215
• 负责人: FREDERICK APPELBAUM
• 金额: $ 5.94万
• 依托单位: FRED HUTCHINSON CANCER CENTER
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-04-01 至 2024-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10430215
• 关键词: Blood; Marrow; Clinical; Trials; Network

Project Summary/Abstract Over the last 15 years, the BMT CTN has effectively addressed key issues in HCT, including donor selection, choice of preparative regimens, prevention of post-transplant infection, prevention and treatment of graft- versus-host disease and the indications for HCT in the treatment of specific diseases, through the conduct of 37 clinical trials. The Fred Hutch Transplant Program has played an important role in the success of the BMT CTN since its inception, serving as one of its Core Clinical Centers. There are a number of features of the Fred Hutch Transplant Program that enhances its value as a Core Clinical Center. (1) The volume of clinical activity at the Hutch allows us to successfully recruit and enroll patients on BMT CTN clinical trials, including patients with rare diseases. The Hutch’s performance in reaching its BMT CTN accrual targets over the last four year has been rated by the BMT CTN as “outstanding.” (2) Our long and deep experience with HCT provides outstanding clinical outcomes. For the past 3 years running, we have exceeded the 95% confidence limits for survival as calculated by the center-specific outcomes measures of the Center for International Blood and Marrow Transplant Research (CIBMTR). (3) The faculty of the Fred Hutch Transplant Program includes a large number of investigators, all focused on various aspects of HCT. The breadth and depth of this group whose NIH funding includes 6 Program Projects, 26 RO1s, and numerous other awards, helps insure that we will continue to provide important scientific contributions to the network. Each year for the last 4 years, our group has been rated as “outstanding” by the BMT CTN for our scientific and administrative efforts. (4) The Fred Hutch has extensive experience with novel cell therapies including stem cell expansion, genetic engineering of T cells, and correction of inborn errors, which are areas of specific interest noted by the NHLBI and the NCI. (5) The faculty of the Fred Hutch have enthusiastically collaborated with other members of the BMT CTN to help achieve the networks research goals over the past funding periods and is committed to continuing to do so.

项目概要/摘要 在过去的 15 年里，BMT CTN 有效解决了 HCT 的关键问题，包括捐助者选择、 准备方案的选择、移植后感染的预防、移植物感染的预防和治疗 抗宿主病和 HCT 在治疗特定疾病中的适应症，通过进行 37 项临床试验。 Fred Hutch 移植计划在 BMT 的成功中发挥了重要作用 CTN自成立以来，一直是其核心临床中心之一。 Fred有很多特点 Hutch 移植计划增强了其作为核心临床中心的价值。 (一)临床活动量 在 Hutch 使我们能够成功招募和招募患者参加 BMT CTN 临床试验，包括患者 患有罕见疾病。过去四年，The Hutch 在实现 BMT CTN 应计目标方面的表现 被 BMT CTN 评为“优秀”。 (2) 我们在 HCT 方面长期而深厚的经验提供了 出色的临床效果。在过去的连续 3 年里，我们已经超过了 95% 的置信限 根据国际血液中心的特定中心结果测量计算的生存率 骨髓移植研究（CIBMTR）。 (3) Fred Hutch 移植项目的教职人员包括一大批 许多研究者都专注于 HCT 的各个方面。这个群体的广度和深度 NIH 资助包括 6 个计划项目、26 个 RO1 和众多其他奖项，有助于确保我们 继续为网络提供重要的科学贡献。过去 4 年里，我们团队每年 由于我们的科学和管理努力，被 BMT CTN 评为“杰出”。 (4) 弗雷德 Hutch 在新型细胞疗法方面拥有丰富的经验，包括干细胞扩增、基因工程 T 细胞和先天性缺陷的纠正，这是 NHLBI 和 NCI 特别感兴趣的领域。 (5) Fred Hutch 的教师与 BMT CTN 的其他成员积极合作， 帮助实现网络在过去资助期间的研究目标，并致力于继续这样做 所以。